HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/1/E238    most recent 00239.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by van den Hoek, A. M. Articles by Pijl, H. Search for Related Content PubMed PubMed Citation Articles by van den Hoek, A. M. Articles by Pijl, H.

Chronic PYY_3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice

¹TNO-Biomedical Research, Gaubius Laboratory; ²Department of Endocrinology and Metabolic Diseases; ³Department of Internal Medicine; and ⁴Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Submitted 19 May 2006 ; accepted in final form 25 August 2006

PYY_3–36 is a gut-derived hormone acting on hypothalamic nuclei to inhibit food intake. We recently showed that PYY_3–36 acutely reinforces insulin action on glucose disposal in mice. We aimed to evaluate effects of PYY_3–36 on energy metabolism and the impact of chronic PYY_3–36 treatment on insulin sensitivity. Mice received a single injection of PYY_3–36 or were injected once daily for 7 days, and energy metabolism was subsequently measured in a metabolic cage. Furthermore, the effects of chronic PYY_3–36 administration (continuous and intermittent) on glucose turnover were determined during a hyperinsulinemic-euglycemic clamp. PYY_3–36 inhibited cumulative food intake for 30 min of refeeding after an overnight fast (0.29 ± 0.04 vs. 0.56 ± 0.12 g, P = 0.036) in an acute setting, but not after 7 days of daily dosing. Body weight, total energy expenditure, and physical activity were not affected by PYY_3–36. However, it significantly decreased the respiratory quotient. Both continuous and intermittent PYY_3–36 treatment significantly enhanced insulin-mediated whole body glucose disposal compared with vehicle treatment (81.2 ± 6.2 vs. 77.1 ± 5.2 vs. 63.4 ± 5.5 µmol·min^–1·kg^–1, respectively). In particular, PYY_3–36 treatment increased glucose uptake in adipose tissue, whereas its impact on glucose disposal in muscle did not attain statistical significance. PYY_3–36 treatment shifts the balance of fuel use in favor of fatty acids and enhances insulin sensitivity in mice, where it particularly promotes insulin-mediated glucose disposal. Notably, these metabolic effects of PYY_3–36 remain unabated after chronic administration, in contrast to its anorexic effects.

diabetes; brain; metabolism; gut hormone

This article has been cited by other articles:

				J. Zhou, R. J. Martin, R. T. Tulley, A. M. Raggio, K. L. McCutcheon, L. Shen, S. C. Danna, S. Tripathy, M. Hegsted, and M. J. Keenan Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1160 - E1166. [Abstract] [Full Text] [PDF]

				P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R39 - R46. [Abstract] [Full Text] [PDF]